The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients

Creative Commons License

Ancin B., Ozercan M. M. , Yilmaz Y., UYSAL S., KUMBASAR U., SARIBAŞ Z., ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.4, pp.1050-1057, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 52 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.55730/1300-0144.5407
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.1050-1057
  • Keywords: Nonsmall cell lung cancer (NSCLC), soluble programmed cell death protein 1 (sPD-1), soluble programmed cell death ligand 1 (sPD-L1), thoracic surgery, PD-L1, PLASMA, EXPRESSION, BLOCKADE, THERAPY
  • Hacettepe University Affiliated: Yes


Background/aim: Significant advances have been achieved in immunotherapy for the treatment of lung cancer. It is known that tumor cells and cells in the tumor microenvironment express high amounts of programmed cell death ligand 1 (PD-L1). These PD-L1s interact with programmed cell death protein 1 (PD-1), causing immunosuppression. The aim of our study is to examine the correlation between the serum sPD-1 and sPD-L1 levels and clinicopathological characteristics in patients with nonsmall cell lung cancer. We also compared our results with the healthy population (control group).